BioPorto’s Board of Directors consists of four member elected by the General Meeting. Collectively, the Board possesses the following competencies:

• Extensive business expertise (economic and financial matters, sales and marketing, IPR, licensing and negotiation)
• Insight into the biotech industry
• International experience

Mr. Carsten Lønfeldt (1947)

M.Sc. (Econ), Copenhagen Business School.

Chairman and board member since 2007.

Until the end of 2006, Carsten Lønfeldt was Group Director in Coloplast A/S following a twenty-year career of management responsibilities in the company within a number of strategic key areas such as economy and finance, IT, HR, planning, corporate control and investor relations. After retiring from Coloplast, Carsten Lønfeldt has concentrated on his efforts at various board positions and is a member of the Advisory Board for OMX The Nordic Exchange, Copenhagen, among others. Based on his wide-ranging management background and insight into the biotech industry, Carsten Lønfeldt provides BioPorto with business expertise, which contributes to BioPorto’s continued strategic development.

Mr. Niels T. Foged (1961)

M.Sc. (Chemical Engineering)

Board member since 2007.

Niels Tækker Foged is Chief Scientific Officer in Visiopharm A/S and has worked with research and development, both in public-sector research positions and in management positions in the biotech industry for most of his career. Until 2006, he was head of research and development for DAKO Denmark A/S, which focuses on development of antibodies for diagnostics, just as BioPorto. Niels Tækker Foged is a Doctor of Veterinary Medicine and the author of a number of internationally recognised scientific articles in fields such as microbiology. The combination of Niels Tækker Foged’s scientific, market-related and management background is an important asset to BioPorto in the Company’s continued focus on research and development of diagnostic products.

Mr. Peter Nordkild (1955)

M.D.

Board member since 2007.

Peter Nordkild is CEO for Adenium Biotech. Peter Norkild was in 2010 CEO for Egalet, and prior to that Chief Commercial Officer and member of the group management for Pharmexa. Peter Nordkild is a qualified physician and has worked for a number of companies within the pharmaceutical industry, from 2000 employed as Senior Vice President, Commercial Operations in Ferring Pharmaceuticals. Primary responsibilities were expansion and growth of Ferring’s operations outside North America and the original EU countries with a particular focus on Japan, Eastern Europe and the Middle East. During the previous 12 years, Peter Nordkild held a number of different positions within Novo Nordisk. Peter Nordkild’s unique international experience is particularly relevant in the continued strategic exploitation of BioPorto’s market-related potential.

Ms. Marianne Weile (1960)

MBA and BA (Biochemistry)

Board member since 2009

Marianne Weile has been with Novozymes since 2000 and is Director for Patents & Licensing. Previously, Marianne Weile was a consultant with Dansk Industri and with Copenhagen Science Park Symbion and over a number of years she has focused on innovation, technology and start-up of companies, including the start-up of her own company. Marianne Weile has solid experience within IPR, licensing and business development which combined with insight into the biotech industry and experience with smaller companies are valuable competencies for the board and the company’s strategic focus on IP rights and licensing agreements.